New anti-Mycobacterium agents: recent advances in patent literature

Bibliography

• HORSBURGH CR, JR.: Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. New Engl. J. Med. (1991) 324:1132–1138.
   Google Scholar
• •Describes the occurrence of mycobacterium avium infections in AIDS patients.
   Google Scholar
• HOOVER DR, SAAH AJ, BACELLAR H et al.: Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. New Engl. J. Med. (1993) 329:1922–1926.
   PubMed Web of Science ®Google Scholar
• •Describes the occurrence of mycobacterium avium infections in AIDS patients.
   Google Scholar
• ELLNER JJ, GOLDBERGER MJ, PARENTI DM: Mycobacte- rium aviumin fection and AIDS: a therapeutic dilemma in rapid evolution. J Infect. Dis. (1991) 163:1326–1335.
   PubMed Web of Science ®Google Scholar
• •Reports the results obtained using various conventional anti-mycobacterium agents in the treatment of M avium infections in AIDS patients.
   Google Scholar
• BENSON C: Treatment of disseminated disease due to the Mycobacterium avium complex in patients with AIDS. Clin. Infect. Dis. (1994) 18 (Suppl. 3):S237–342.
   Google Scholar
• •Reports the results obtained using various conventional anti-mycobacterium agents in the treatment of M avium infections in AIDS patients.
   Google Scholar
• INDERLIED CB, YOUNG LS, YAMADA JK: Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob. Agents Chemother. (1987) 31:1697–1702.
   PubMed Web of Science ®Google Scholar
• ••Reports useful information concerning the drugs currentlyused in the multi-drug treatment or M. tuberculosis infections.
   Google Scholar
• RASTOGI N, GOH KS, GUILLOU N, LABROUSSE V: Spectrum of drugs against atypical mycobacteria: how valid is the current practice of drug susceptibility testing and the choice of drugs? Zentralbl. Bakteriol (1992) 277:474–484.
   PubMedGoogle Scholar
• ••Reports useful information concerning the drugs currentlyused in the multi-drug treatment or M. tuberculosis infections.
   Google Scholar
• MASUR H: Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. New Eng]. J. Med. (1993) 329:898–904.
   Google Scholar
• ••Reports useful information concerning the drugs currentlyused in the multi-drug treatment or M. tuberculosis infections.
   Google Scholar
• ELLNER JJ, GOLDBERGER MJ, PARENTI DM: Mycobacte- rium avium infection and AIDS: a therapeutic dilemma in rapid evolution. J Infect. Dis. (1991) 163:1326–1335.
   PubMed Web of Science ®Google Scholar
• ••Deals with the drugs active towards M. avium infections.
   Google Scholar
• YAJKO DM, NASSOS PS, SANDERS CA, HADLEY WK: Effects of antimicrobial agents on survival ofMycobac-terium avium complex inside alveolar macrophages obtained from patients with human immunodefi-ciency virus infection. Antimicrob. Agents Chemother. (1991) 35:1621–1625.
   PubMed Web of Science ®Google Scholar
• ••Deals with the drugs active towards M. avium infections.
   Google Scholar
• INDERLIED CB, KEMPER CA, BERMUDEZ LEM: The Mycobacterium avium complex. Gun. Microbic)]. Rev. (1993) 6:266–310.
   Google Scholar
• ••Reports the results obtained in the use of macrolides in thetreatment of M avium complex.
   Google Scholar
• DAUTZENBERG B: Clinical trials in Mycobacterium avium therapy: lessons to take home. Res. Microbiol. (1994) 145:197–206.
   PubMed Web of Science ®Google Scholar
• CYNAMON MH, GIMI R, GYENES F et al: Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. J. Med. Chem. (1995) 38:3902–3907.
   PubMed Web of Science ®Google Scholar
• ••This paper describes the results obtained in the use ofvarious pyrazinoic acid derivatives as in vitro agents against M. tuberculosis and M avium.
   Google Scholar
• COLE ST, BROSCH R, PARKHILL J et al: Deciphering the biology of M tuberculosis from the complete genome sequence. Nature (1998) 393(6685)537–544.
   Google Scholar
• ••This paper reports the genome of M. tuberculosis and willbe useful for the design of new agents for gene therapy of mycobacterium infections.
   Google Scholar
• SAVAGE JE, OSULLIVAN JF, ZEIS BM, ANDERSON R: Investigation of the structural properties of dihydro-phenazines which contribute to their pro-oxidative interactions with human phagocytes. J. Antimicrob. Chemother. (1989) 23(5):691–700.
   PubMed Web of Science ®Google Scholar
• •Describes the anti-mycobacterium activity of dihydrophe-nazine derivatives.
   Google Scholar
• AGRAWAL KC, BEARS KB, SEHGAL RK, BROWN JN, RIST PE, RUPP WD: Potential radiosensitizing agents. Dinitroimidazoles. J Med. Chem. (1979) 22:583–586.
   PubMed Web of Science ®Google Scholar
• •Reports the use of imidazol derivatives as anticancer agents.
   Google Scholar
• STOVER CK, WARRENER P, VANDEVANTER DR et al.: A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature (2000) 405 (6789):962–662.
   PubMed Web of Science ®Google Scholar
• ••This article describes the mechanism of action ofnitroimidazopyran.
   Google Scholar